WideMed Ltd. (TASE:WDMD) has obtained Health Canada marketing approval for its sleep apnea monitoring systems Morpheus, Morpheus OX, and Morpheus HX, after the company provided that they complied with the safety and efficacy standards set out in the Canadian Medical Device Regulations.
With the Canada Health approval, Widemed plans to expand use of the Morpheus HX system with GE Healthcare's Mars VLS device for the Canadian market, as part of the joint marketing agreement between the two companies.
Widemed CEO Anya Eldan said, "Since obtaining US Food and Drug Administration (FDA) approval for the Morpheus HX system, the company has been working hard to obtain additional regulatory certifications in order to expand use of its proprietary products to other markets around the world. Widemed and GE Healthcare will launch marketing in Canada at the Canadian Cardiology Congress later this month."
Widemed's Morpheus monitors are approved for marketing in the US and Europe.
Widemed's share price rose 5.5% in morning trading to NIS 0.47, giving a market cap of NIS 10 million.
Published by Globes [online], Israel business news - www.globes-online.com - on October 5, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011